Abeona Therapeutics (ABEO) Peer Comparison

$5.46

$-0.02 (-0.36%)

As on 11-Sep-2026 13:36EDT

Market cap

$343 Mln

Revenue (TTM)

$26 Mln

P/E Ratio

--

P/B Ratio

2.7

Div. Yield

0 %

Edit

	Abeona Therapeutics (ABEO)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	343	17,747	16,504	14,622	12,506
Revenue ($ Mln)	26	1,054	2,782	2,436	1,664
Net Profit ($ Mln)	-62.89	755.85	491.50	860.62	413.60
Net Margin (%)	-246.42	71.69	17.67	35.33	24.86
RoE (%)	-43.78	--	110.09	42.98	430.03
Price to Earnings	--	20.93	34.72	18.56	32.31
Price-To-Book	2.67	10.51	38.18	7.95	86.71

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Abeona Therapeutics (ABEO)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	25.52	1,054.37	2,782.29	2,435.92	1,663.74
Cost of Revenue	11.07	103.47	1,982.07	85.67	363.07
Gross Profit	4.29	588.53	760.62	2,236.43	1,091.18
Operating Expenses	98.07	841.45	216.81	1,378.74	356.18
Operating Profit (EBIT)	-83.62	109.45	583.40	971.51	944.49
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-78.30	101.11	598.92	1,035.47	583.34
Provision for Tax	-15.41	-654.74	107.42	174.84	169.74
Profit after Tax (Net Income)	-62.89	755.85	491.50	860.62	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Abeona Therapeutics (ABEO)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	128.06	1,435.90	433.86	1,843.76	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	26.64	384.48	187.89	288.55	2,089.43
Current Liabilities	24.81	464.70	1,435.43	361.93	344.44
Total Liabilities	219.57	1,302.02	1,975.47	2,844.42	2,525.32

Assets ($ Mln)

	Abeona Therapeutics (ABEO)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	14.93	895.24	1,006.90	1,243.41	1,644.38
Current Assets	164.58	1,389.84	1,050.29	1,250.82	933.02
Total Assets	219.57	1,302.02	1,975.47	2,844.42	2,525.32
Total Debt*	19.87	449.89	120.10	165.93	2,146.65
Net Current Assets	139.77	925.52	-385.14	888.90	588.59

Cashflow ($ Mln)

	Abeona Therapeutics (ABEO)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-76.33	51.77	713.22	884.27	651.56
Cash Flow from Investing Activities	105.03	-8.15	-31.14	350.44	-545.81
Cash from Financing Activities	26.04	34.89	-860.39	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Abeona Therapeutics (ABEO)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	56.66	-30.01	53.56	32.82	15.61
ROE (%)	-43.78	163.18	110.09	42.98	430.03
ROA (%)	-25.93	31.68	15.64	29.32	16.19
EBIT Margin (%)	-293.83	5.73	21.13	31.04	36.28
Net Margin (%)	-246.42	71.69	17.67	35.33	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Abeona Therapeutics (ABEO)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	392.47	114.85	24.67	9.23	41.15
EBIT Growth (%)	-197.52	136.39	18.70	-3.99	-14.99
Net Profit Growth (%)	-209.86	378.76	17.50	42.89	-25.78
EPS Growth (%)	-297.92	353.27	26.84	50.42	-23.48
Book Value Growth (%)	-8.55	816.12	164.02	-0.70	-55.81

Valuation Ratios

	Abeona Therapeutics (ABEO)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	4.90	-59.76	36.06	15.79	24.99
Price / Book Value	2.19	-80.42	35.44	5.72	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	2.32	-121.54	28.08	12.44	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Abeona Therapeutics (ABEO)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	0.01	0.27	0.00	0.00	13.50
Short term debt to equity ratio	0.11	0.05	0.00	0.00	1.46
Current Ratio	6.63	2.99	0.73	3.46	2.71
Quick Ratio	6.40	2.32	0.73	3.38	2.31
Interest Coverage	-22.65	1.62	--	--	29.73

Operating Efficiency Ratios

	Abeona Therapeutics (ABEO)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	38.75	21.25	15.88	13.74	27.40
Asset Turnover	0.11	0.44	0.89	0.83	0.65
Receivable days	262.55	85.52	50.42	43.48	98.04
Inventory Days	654.80	1,056.70	--	96.17	190.34
Payable days	1,350.61	331.01	6.26	147.97	18.62
Cash Conversion Cycle	-433.26	811.21	--	-8.32	269.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly